Biotech firm Freenome has raised $254 million in funding, led by Roche and supported by existing and new investors. The funding will propel Freenome's development of blood tests for early cancer detection, focusing on single-cancer and tailored multi-cancer tests using its multiomics platform. Freenome's innovative approach employs computational biology and machine learning to create advanced screening tools, addressing the critical need for improved cancer screening.
The company's initial programs concentrate on colorectal and lung cancers, with ongoing registrational studies, while broader multi-cancer research programs, like the Vallania Study, aim to involve over 10,000 participants.
The significant funding infusion positions Freenome to make early cancer detection more accessible and actionable. The company collaborates with biopharma and diagnostic partners to explore the potential of its platform in detecting minimal residual disease non-invasively. Freenome's success underscores its commitment to transforming cancer screening through cutting-edge technology and large-scale clinical studies.
Click here to read the original news story.